POLE and colorectal carcinoma: Patients with POLE mutations who benefit from immunotherapy have recently been reported, which indicates that the POLE gene could be a potential marker for treating CRC patients; however, its clinical characteristics and potential heterogeneity should not be overlooked.11, 12, 13